Skip to content
Inciteful Med

Treatment Strategy and Medications for GCA

Last updated:

Giant Cell Arteritis (GCA) requires immediate emergency treatment with high-dose steroids like prednisone to prevent permanent vision loss. Over 12 to 18 months, the steroid dose is slowly tapered. Biologic medications like tocilizumab are often added to reduce steroid use and manage side effects.

Key Takeaways

  • • Emergency high-dose steroid treatment must begin the moment Giant Cell Arteritis is suspected to prevent permanent blindness.
  • • Steroid doses must be slowly and carefully tapered over 12 to 18 months to keep the disease from returning.
  • • Biologic medications like tocilizumab can be used alongside steroids to reduce the total amount of steroids a patient needs.
  • • Patients on high-dose steroids need active monitoring to manage side effects affecting bone health, blood sugar, and blood pressure.
  • • Never stop or change your steroid dose without medical supervision due to the risk of severe blood pressure drops and disease flares.

The goal of treating Giant Cell Arteritis (GCA) is two-fold: first, to immediately stop the inflammation to protect your vision and second, to transition to a long-term plan that controls the disease with the fewest possible side effects [1][2]. Because the risk of permanent blindness is so high, treatment is an emergency that must begin the moment GCA is suspected [3][4].

The Emergency Phase: Glucocorticoids

Glucocorticoids (often called steroids, like prednisone) are the absolute cornerstone of GCA therapy [1][5]. They work by rapidly “turning off” the immune system’s attack on your arteries [6].

  • Initial Dose: For most patients, this starts with high-dose oral prednisone (typically 40–60 mg per day) [1][5].
  • Vision Threats: If you are already experiencing vision loss, doctors may use “pulse” therapy, which involves very high doses of methylprednisolone delivered through an IV for about three days to provide the strongest possible protection for your sight [7][8].
  • Tapering: Once the disease is under control, your doctor will slowly reduce (taper) the dose. This process is very gradual, often taking 12 to 18 months, to prevent the disease from “flaring” or returning [9][5].

The Long-Term Phase: Biologic Therapy

While steroids are life-saving, taking them at high doses for a long time can be hard on the body [10][6]. To help reduce the total amount of steroids you need, doctors often use steroid-sparing agents.

  • Tocilizumab: This is a biologic medication (an IL-6 receptor antagonist) that targets a specific protein involved in GCA inflammation [1][11].
  • Benefits: Research shows that adding tocilizumab to a steroid taper significantly increases the chances of staying in remission and allows patients to take a much lower total dose of steroids over time [12][13][14].
  • Safety Warnings: As a powerful immunosuppressant, tocilizumab carries risks, including an increased risk of severe infections, potential gastrointestinal perforations, or liver enzyme abnormalities [15]. Regular blood tests are required to monitor these risks safely.
  • Alternative: In some cases, a medication called methotrexate may also be used to help lower steroid needs [1][16].

Managing Side Effects

Because GCA treatment often lasts a year or more, managing the side effects of medications is a critical part of your care [17][18].

  • Bone Health: High-dose steroids can weaken bones, leading to osteoporosis and fractures [19][18]. Most patients should take calcium, Vitamin D, and sometimes a bone-strengthening medication (bisphosphonate) [20][9].
  • Blood Sugar and Pressure: Steroids can cause or worsen diabetes and high blood pressure [19][10]. Regular monitoring of your blood sugar and A1c is essential [21][22].
  • Cardiovascular Health: GCA itself can increase the risk of heart-related issues [23][24]. However, the routine use of low-dose aspirin is no longer recommended for all GCA patients due to bleeding risks, unless specifically prescribed for other independent cardiovascular conditions.

Important Reminder: Never stop or change your dose of steroids without talking to your doctor. Stopping steroids suddenly can cause a dangerous drop in blood pressure and a return of your GCA symptoms [18].

Frequently Asked Questions

Why do I need to start taking steroids immediately for GCA?
Steroids are used immediately to rapidly turn off the immune system's attack on your arteries. This emergency treatment is absolutely critical to protect your vision and prevent permanent blindness.
How long will I have to take steroids for Giant Cell Arteritis?
Steroid treatment usually involves starting with a high dose and slowly tapering it down over 12 to 18 months. This very gradual reduction is necessary to prevent the disease from flaring up or returning.
What is tocilizumab and why is it prescribed?
Tocilizumab is a biologic medication that targets a specific protein involved in GCA inflammation. Doctors prescribe it as a 'steroid-sparing' agent to help you successfully reduce your steroid dose and stay in remission while minimizing long-term side effects.
How can I protect my bones while taking high-dose steroids?
High-dose steroids can weaken your bones and lead to osteoporosis. To protect your bone health, doctors typically recommend taking calcium and Vitamin D supplements, and sometimes prescribe bone-strengthening medications called bisphosphonates.
Why can't I just stop taking my steroids when I feel better?
Stopping steroids suddenly is dangerous because it can cause a severe drop in blood pressure. It can also lead to an immediate return of your GCA symptoms, which could threaten your vision. Always follow your doctor's exact tapering schedule.

Questions for Your Doctor

  • • What is my specific starting dose of steroids, and what is our target timeline for tapering?
  • • Is tocilizumab appropriate for my case to help reduce the total amount of steroids I'll need?
  • • Since I'm on high-dose steroids, what medications should I take to protect my bones from osteoporosis?
  • • How often should we be checking my blood sugar and blood pressure while I am on this treatment?
  • • What symptoms should I look for that would indicate the disease is 'flaring' during the tapering process?

Questions for You

  • • Have you noticed any new mood changes, difficulty sleeping, or increased thirst since starting your medication?
  • • Are you keeping a daily log of your steroid dose so you can easily track your tapering schedule?
  • • Have you had a bone density (DEXA) scan recently to establish a baseline for your bone health?
  • • Do you have a plan for regular exercise and a diet that supports bone health and blood sugar control?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Treatment of giant cell arteritis: what is in the pipeline?]

    Holle JU, Moosig F

    Zeitschrift fur Rheumatologie 2020; (79(6)):516-522 doi:10.1007/s00393-020-00808-0.

    PMID: 32399619
  2. 2

    Orbital MRI Findings in a Patient With Giant Cell Arteritis (GCA): A Case Report.

    Alhawiti S, AlSulaim T

    Cureus 2023; (15(11)):e49507 doi:10.7759/cureus.49507.

    PMID: 38152789
  3. 3

    Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study.

    Dumont A, Lecannuet A, Boutemy J, et al.

    Seminars in arthritis and rheumatism 2020; (50(2)):335-341 doi:10.1016/j.semarthrit.2019.09.008.

    PMID: 32192630
  4. 4

    Giant Cell Arteritis: Can Simple Ultrasound Examination Prevent Complex Consequences?

    Stańska W, Kruszewski R, Juszkiewicz A, et al.

    Diagnostics (Basel, Switzerland) 2024; (14(18)) doi:10.3390/diagnostics14182071.

    PMID: 39335750
  5. 5

    Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.

    Buttgereit F, Dejaco C, Matteson EL, Dasgupta B

    JAMA 2016; (315(22)):2442-58 doi:10.1001/jama.2016.5444.

    PMID: 27299619
  6. 6

    Giant cell arteritis and innovative treatments.

    Costanzo G, Ledda AG, Sambugaro G

    Current opinion in allergy and clinical immunology 2023; (23(4)):327-333 doi:10.1097/ACI.0000000000000923.

    PMID: 37357797
  7. 7

    Corticosteroid Usage in Giant Cell Arteritis.

    Kanakamedala A, Hussain M, Kini A, et al.

    Neuro-ophthalmology (Aeolus Press) 2021; (45(1)):17-22 doi:10.1080/01658107.2020.1767656.

    PMID: 33762783
  8. 8

    Giant cell arteritis presenting as bilateral anterior ischemic optic neuropathy: a biopsy-proven case report in Chinese patient.

    Tian G, Chen W, Chen Q, et al.

    BMC ophthalmology 2018; (18(1)):282 doi:10.1186/s12886-018-0953-5.

    PMID: 30376812
  9. 9

    [Treatment of giant cell arteritis].

    Samson M, Greigert H, Ghesquière T, Bonnotte B

    Presse medicale (Paris, France : 1983) 2019; (48(9)):968-979 doi:10.1016/j.lpm.2019.06.002.

    PMID: 31324351
  10. 10

    [Giant Cell Arteritis].

    Suzuki F, Kimura K

    Brain and nerve = Shinkei kenkyu no shinpo 2021; (73(5)):496-502 doi:10.11477/mf.1416201791.

    PMID: 34006681
  11. 11

    The role of biologics in the treatment of giant cell arteritis.

    González-Gay MA, Pina T, Prieto-Peña D, et al.

    Expert opinion on biological therapy 2019; (19(1)):65-72 doi:10.1080/14712598.2019.1556256.

    PMID: 30513026
  12. 12

    New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.

    Stone JH, Spotswood H, Unizony SH, et al.

    Rheumatology (Oxford, England) 2022; (61(7)):2915-2922 doi:10.1093/rheumatology/keab780.

    PMID: 34718434
  13. 13

    Current advances in giant cell arteritis.

    Kaushik M, Ponte C, Mollan SP

    Current opinion in neurology 2021; (34(1)):133-141 doi:10.1097/WCO.0000000000000889.

    PMID: 33230039
  14. 14

    Profile of tocilizumab and its potential in the treatment of giant cell arteritis.

    Mollan SP, Horsburgh J, Dasgupta B

    Eye and brain 2018; (10()):1-11 doi:10.2147/EB.S127812.

    PMID: 29416384
  15. 15

    Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis.

    Evans J, Steel L, Borg F, Dasgupta B

    RMD open 2016; (2(1)):e000137 doi:10.1136/rmdopen-2015-000137.

    PMID: 26819753
  16. 16

    Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review.

    Raleigh MF, Stoddard J, Darrow HJ

    American family physician 2022; (106(4)):420-426.

    PMID: 36260899
  17. 17

    Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice.

    Craig G, Knapp K, Salim B, et al.

    Rheumatology and therapy 2021; (8(1)):529-539 doi:10.1007/s40744-021-00290-3.

    PMID: 33638132
  18. 18

    A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects.

    Perrineau S, Ghesquière T, Charles P, et al.

    Clinical and experimental rheumatology 2021; (39 Suppl 129(2)):155-160 doi:10.55563/clinexprheumatol/0nd4kk.

    PMID: 33938796
  19. 19

    Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.

    Wilson JC, Sarsour K, Collinson N, et al.

    Seminars in arthritis and rheumatism 2017; (46(6)):819-827 doi:10.1016/j.semarthrit.2016.11.006.

    PMID: 28040244
  20. 20

    Level of Adherence to Prophylactic Osteoporosis Medication amongst Patients with Polymyalgia Rheumatica and Giant Cell Arteritis: A Cross-Sectional Study.

    Emamifar A, Gildberg-Mortensen R, Andreas Just S, et al.

    International journal of rheumatology 2015; (2015()):783709 doi:10.1155/2015/783709.

    PMID: 26491449
  21. 21

    Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis.

    Broder MS, Sarsour K, Chang E, et al.

    Seminars in arthritis and rheumatism 2016; (46(2)):246-252 doi:10.1016/j.semarthrit.2016.05.009.

    PMID: 27378247
  22. 22

    Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis.

    Best JH, Kong AM, Smith DM, et al.

    ClinicoEconomics and outcomes research : CEOR 2019; (11()):799-807 doi:10.2147/CEOR.S228400.

    PMID: 31920351
  23. 23

    Is Giant Cell Arteritis Associated with Increased Risk of Cardiovascular Disease? A Meta-Analysis.

    Jain H, Shahzad M, Patel N, et al.

    Cardiology in review 2025; doi:10.1097/CRD.0000000000000928.

    PMID: 40314449
  24. 24

    Myocardial infarction during giant cell arteritis: A cohort study.

    Greigert H, Zeller M, Putot A, et al.

    European journal of internal medicine 2021; (89()):30-38 doi:10.1016/j.ejim.2021.02.001.

    PMID: 33610415

This page provides educational information about Giant Cell Arteritis (GCA) treatments and medications. It does not replace professional medical advice, and you should always consult your doctor before changing your steroid dose or treatment plan.

Stay up to date

Get notified when new research about Giant cell arteritis is published.

No spam. Unsubscribe anytime.